our pipeline
Targeting ACDs in which serotonin is disrupted
CT38
Cortene’s peptide agonist, which is selective for CRFR2, has completed multiple studies including:
test-tubes in vitro studies
mouse in vivo studies
in multiple species
man a Phase 1 clinical trial
in healthy humans
Group a proof-of-concept Phase 2
clinical trial in patients
These have enabled us to determine the safe and effective dosing required to downregulate CRFR2. They have also confirmed that CT38 binds only to CRFR2 and is cleared from the body within hour
Pipeline
Our platform allows CT38 to be utilized in several indications.
We are ready to begin Phase 2 clinical trials in Parkinson’s and Alzheimer’s.
Indication
Animal
Phase 1
Phase 2
Phase 3
Parkinson's
Alzheimer's
MEcfs